LLY241101C960000
- 0.04
- -0.04-50.00%
Eli Lilly and Co Newsroom
Today's Analyst Rating | Amazon Price Target Raised to $250 by J.P. Morgan, Meta Platforms Price Target Raised to $630 by Barclays
Earnings Miss: Eli Lilly and Company Missed EPS By 31% And Analysts Are Revising Their Forecasts
Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
Eli Lilly and Co Options Spot-On: On October 31st, 103.23K Contracts Were Traded, With 345.79K Open Interest
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
Eli Lilly 'Well-Positioned' for Growth Into 2025 Despite Q3 Volatility, UBS Says
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next. -- Barrons.com
Live On CNBC, Stephanie Link Announces Bought More Eli Lilly And Company
Biogen Slips as Morgan Stanley Downgrades on Leqembi Launch
Halloween Market Falls, Scared of Meta and Microsoft CapEx | Live Stock
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,100
Eli Lilly Is Maintained at Buy by B of A Securities
Express News | Elektrofi Inc: Financing Led by Novo Holdings, Others With Participation From Eli Lilly and Company
Express News | Elektrofi Inc: Announces Oversubscribed $112.25 Mln Series C Financing
Eli Lilly Analyst Ratings
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating